Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also cleared for use by children as young as two years old, for use by women with diabetes who are pregnant, and for wear time up to 15 days ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine reinforce the long-term safety and effectiveness of MitraClip for treating secondary mitral regurgitation (MR) Results show minimally invasive mitral valve repair in advanced heart failure patients reduces hospitalizations and deaths and provides durable reduction in the severity of MR Historically, advanced heart failure patients battling secondary MR (a leaky mitral valve caused by problems affecting other areas of the heart) have been challenging to treat as a result of limited therapy options ABBOTT PARK, Ill., March 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure.

Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device

Late-breaking data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine demonstrate TriClip was superior to medical therapy with significant improvements in quality of life and tricuspid regurgitation (TR) Findings show TriClip, an investigational device in the U.S. to treat a leaky tricuspid valve, demonstrated safety and met the primary endpoint ABBOTT PARK, Ill., March 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data for the TriClip™ transcatheter edge-to-edge repair (TEER) system, a first-of-its-kind minimally invasive device designed specifically for tricuspid heart valve repair.

New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation

AbbVie

Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.

2 High-Yield Dividend Stocks to Buy in March

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic.

Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?

Realty Income Corp

The road to wealth is long, but it'll be a bit shorter with the right investments.

Build Your Wealth by Buying and Holding These 2 Dividend Stocks for at Least 20 Years

Black Hills

Emerson Electric

Federal Realty Investment Trust

Johnson & Johnson

Coca-Cola

Leggett & Platt

Lowe's

Altria

National Fuel Gas

Northwest Natural Gas

Sysco

Universal Corp

V.F.

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 47 Dividend Kings screened as of February 24, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 15.54%-31.75% topped-by NFG & VFC.

March Dividend Kings: 5 Buys, 4 To Watch

The company's specialized heart care products appear to prove their value in clinical testing.

Why Abbott Laboratories Stock Bumped Higher Today

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder's immediate and complete closure of the LAA compared to Watchman‡ Findings underscore the importance of innovative, minimally invasive treatment options for people battling complex heart conditions like aortic stenosis and atrial fibrillation ABBOTT PARK, Ill., Feb. 28, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data for its next-generation Navitor™ transcatheter aortic valve implantation (TAVI) system.

Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices

Apple

DexCom

The continuous glucose monitoring market could heat up.

Should Abbott and DexCom Investors Be Worried About Apple's Latest News?

Medtronic

Exxon Mobil

Dividend Stocks To Buy Now? 3 For Your Watchlist

One of these top dividend stocks is a far more compelling buy today.

Better Dividend Stock: Abbott Laboratories or Medtronic?

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 - Abbott Laboratories (NYSE:ABT), Azenta (NASDAQ:AZTA)

Automatic Data Processing

Clorox

Ecolab

Essex Property Trust

McCormick

Nordson

J. M. Smucker

S&P Global

Stanley Black & Decker

T. Rowe Price Group

Walgreens

West Pharmaceutical Services

NOBL started the year off with a gain of 3.23% in January; it is thus far not faring as well in February, but the ETF is still positive year-to-date. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

My Best Dividend Aristocrats For March 2023

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Why Is Abbott (ABT) Down 7.7% Since Last Earnings Report?

Both stocks should benefit from the growth in diabetes care.

Better Buy: Abbott Laboratories or DexCom Stock?

Both stocks are trading at a similar valuation of a little over 4x trailing revenues.

Is Abbott Stock A Better Pick Over This Pharmaceuticals Bellwether?

Aflac

A. O. Smith

Air Products and Chemicals

Franklin Resources

Cardinal Health

Caterpillar

Cincinnati Financial

Colgate-Palmolive

Cintas Corp

Chevron

Expeditors International of Washington

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Kimberly-Clark

New Linde PLC

I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process and comparing the results to NOBL and SCHD.

Selecting Dividend Aristocrats Using SCHD Methodology - Falling Behind

The company's glucose monitoring business might come under some serious pressure.

Why Abbott Laboratories Stock Sank Today

The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott Laboratories' baby-formula business, the company said.

Abbott Laboratories under SEC and FTC investigation over baby-formula business

The SEC's enforcement division sent a subpoena to Abbott in December requesting information about its powder infant-formula business and related public disclosures, the company said Friday in a securities filing.

Abbott Baby-Formula Business Under Investigation By SEC, FTC

ABBOTT PARK, Ill., Feb. 17, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share.

Abbott Declares 397th Consecutive Quarterly Dividend

A new study published in Science Translational Medicine could introduce a profitable opportunity for makers of seizure drug medications. The discovery has immense medical implications, of course, but it could lead to a windfall for investors, particularly those holding Abbott Laboratories (NYSE: ABT) and AbbVie, Inc (NYSE: ABBV) shares.

How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula

News for Abbott Labs Stock (ABT)